The FDA Approves New Drug for a Skin Condition That Affects 32 Million Americans

By ·
The FDA Approves New Drug for a Skin Condition That Affects 32 Million Americans featured image

This week the U.S. Food and Drug Administration (FDA) approved Eucrisa (crisaborole) ointment to treat mild to moderate eczema (atopic dermatitis) in patients two years of age and older.

You May Also Like: 7 Common Skin Care Conditions and Solutions

More commonly referred to as eczema, atopic dermatitis is a chronic inflammatory skin disease. The National Eczema Association reports that a substantial number of the U.S. population has symptoms of eczema—31.6 million people have eczema, and at least 17.8 million have moderate to severe eczema or atopic dermatitis.

“Today’s approval provides another treatment option for patients dealing with mild to moderate atopic dermatitis,” said Amy Egan, deputy director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research.

The new ointment is intended to be applied topically twice daily. The most common side effect of Eucrisa is application site pain, including burning or stinging.

Find a Doctor

Find a NewBeauty "Top Beauty Doctor" Near you

Give the Gift of Luxury

NewBeauty uses cookies for various reasons, including to analyze and improve its content and advertising. Please review our Privacy Policy and Terms of Use for more about how we use this data. By continuing to use this site, you agree to these policies.